Avelumab: Phase III started

Merck and Pfizer began the open-label, international Phase III JAVELIN Lung 200 trial to compare 10 mg/kg IV avelumab every 2 weeks vs. 75 mg/m 2 IV docetaxel every 3 weeks in about 650 patients whose...